Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment.

In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy.

Related References:

1. Januzzi, J. L., Del Prato, S., Rosenstock, J., Butler, J., Ezekowitz, J., Ibrahim, N. E., Lam, C. S. P., Marwick, T., Wilson Tang, W. H., Liu, Y., Mohebi, R., Urbinati, A., Zannad, F., & Perfetti, R. (2024). Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial. Cardiovascular diabetology, 23(1), 49. https://doi.org/10.1186/s12933-024-02135-z
2. Januzzi, J. L., Jr, Butler, J., Del Prato, S., Ezekowitz, J. A., Ibrahim, N. E., Lam, C. S. P., Lewis, G. D., Marwick, T. H., Rosenstock, J., Tang, W. H. W., Zannad, F., Lawson, F., Perfetti, R., & Urbinati, A. (2023). Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. American heart journal, 256, 25–36.
3. Stanton, A. M., Vaduganathan, M., Chang, L. S., Turchin, A., Januzzi, J. L., Jr, & Aroda, V. R. (2021). Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. Current diabetes reports, 21(10), 41. https://doi.org/10.1007/s11892-021-01407-2